


RECEIVED
CENTRAL FAX CENTER
JUN 26 2008

AMENDMENT TRANSMITTAL LETTER				Docket No. ASZD-P01-228	
Application No. 09/423,037	Filing Date February 22, 2000	Examiner J. A. Dunston	Art Unit 1636		
Applicant(s): Heery et al.					
Invention: INHIBITORS OF NUCLEAR PROTEIN/NUCLEAR RECEPTOR INTERACTION					
TO THE COMMISSIONER FOR PATENTS					
Transmitted herewith is an amendment in the above-identified application.					
The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims	35	- 56 =		x 50.00	0.00
Independent Claims	1	- 3 =		x 200.00	0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					
Other fee (please specify): Extension for response within third month					1,050.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:					1,050.00
<input checked="" type="checkbox"/> Large Entity <input type="checkbox"/> Small Entity					
<input type="checkbox"/> No additional fee is required for this amendment.					
<input checked="" type="checkbox"/> Please charge Deposit Account No. <u>18-1945</u> in the amount of \$ <u>1,050.00</u> . A duplicate copy of this sheet is enclosed.					
<input type="checkbox"/> A check in the amount of \$ _____ to cover the filing fee is enclosed.					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
<input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. <u>18-1945</u> as described below. A duplicate copy of this sheet is enclosed.					
<input checked="" type="checkbox"/> Credit any overpayment.					
<input checked="" type="checkbox"/> Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.					
 David P. Halstead, J.D., Ph.D. Attorney/Agent Reg. No.: 44,735				Dated: <u>June 26, 2008</u>	
ROPES & GRAY LLP One International Place Boston, Massachusetts 02110 (617) 951-7615					
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300, on the date shown below. Dated: <u>06/26/08</u> Signature: <u>Scott Whittemore</u> (Scott Whittemore)					

11155800_1.DOC

RECEIVED
CENTRAL FAX CENTER

JUN 26 2008

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300, on the date shown below.

Dated: 06/26/08 Signature: Scott Whittemore
(Scott Whittemore)

Docket No.: ASZD-P01-228
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Heery et al.

Application No.: 09/423,037

Confirmation No.: 6259

Filed: February 22, 2000

Art Unit: 1636

For: INHIBITORS OF NUCLEAR
PROTEIN/NUCLEAR RECEPTOR
INTERACTION

Examiner: J. A. Dunston

AMENDMENT IN RESPONSE TO NON-FINAL OFFICE ACTION

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

In response to the Office Action dated January 2, 2008, please amend the above-identified U.S. patent application as follows. Applicants are filing a Petition for Extension of Time herewith.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 6 of this paper.